Menu
Back to Journals » Clinical Ophthalmology » Volume 7
Emerging roles for antiangiogenesis factors in management of ocular disease
Authors Saeed M, Gkaragkani E, Ali K
Received 4 December 2012
Accepted for publication 22 January 2013
Published 13 March 2013 Volume 2013:7 Pages 533—543
DOI https://doi.org/10.2147/OPTH.S31016
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Muhammad Usman Saeed,1 Evangelia Gkaragkani,1 Kashif Ali2
1The Sutton Eye Unit, Epsom and St Helier’s University Hospitals NHS Trust, London, UK; 2Department of Ophthalmology, Countess of Chester Hospital NHS Foundation Trust, Chester, UK
Abstract: The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatment with new treatment options and has had a considerable financial impact on health care resources. Anti-VEGFs have been used in the treatment of all age groups of the population ranging from infants where it is used for treatment of retinopathy of prematurity to the elderly where it is used in exudative macular eegeneration.
Keywords: ranibizumab, bevacizumab, pegaptanib, retina, aflibercept, indications
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.